Search

Solitary fibrous tumor is a rare mesenchymal neoplasm arising from the serosal membranes, dura, and deep soft tissues. A solitary fibrous tumor of the CNS, head, neck, and spine can be challenging to diagnose on imaging. Preoperative consideration of a solitary fibrous tumor is critical, especially in the setting of a high-grade solitary fibrous tumor, which has a high recurrence rate and metastatic potential. This review highlights multimodal imaging features of solitary fibrous tumors, including CT, MR imaging (SWI, MRA, MRS, DWI, and perfusion), FDG PET, and catheter-directed angiography. Radiologic pathologic correlations are also provided. The management of solitary fibrous tumor is a team effort orchestrated with surgery, radiation oncology, and neurointerventional and diagnostic radiology. For high-grade solitary fibrous tumors, preoperative tumor embolization followed by surgical resection and adjuvant radiation therapy improves patient outcomes. Additional whole-body staging and follow-up MR imaging are important to evaluate recurrence or distal metastasis. Learning Objective: To recognize the multimodal imaging appearance of solitary fibrous tumor in the CNS, head and neck, and spine. [ABSTRACT FROM AUTHOR]

Akira Suda,1 Saki Hattori,1 Ikuko Kishida,1,2 Masatoshi Miyauchi,1 Yohko Shiraishi,1 Mami Fujibayashi,3 Natsuki Tsujita,4 Chie Ishii,2 Norio Ishii,2 Toshio Moritani,5 Yoshio Hirayasu1,6 1Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, 2Department of Psychiatry, Fujisawa Hospital, Kanagawa, 3Division of Physical and Health Education, Setsunan University, Osaka, 4Graduate School of Human and Environmental Studies, Kyoto University, 5Department of Health and Sports Sociology, Faculty of General Education, Kyoto Sangyo University, Kyoto, 6Department of Psychiatry, Hirayasu Hospital, Okinawa, Japan Objective: Long-acting injections (LAIs) of antipsychotics show distinct pharmacokinetic profiles from oral antipsychotics (OAPs). Although there may be differences in adverse event frequency, any differences in their effects on autonomic nervous system (ANS) remain unclear. Patients and methods: In total, 270 schizophrenic patients were recruited in this study: 241 received OAPs (risperidone, olanzapine, quetiapine, or aripiprazole) and 29 received LAIs (risperidone LAI, aripiprazole LAI, or paliperidone palmitate) as monotherapy. Heart rate variability was measured as an index of ANS activity, and the low-frequency (0.03–0.15 Hz) component, high-frequency (0.15–0.40 Hz) component, and total power (0.03–0.40 Hz) were calculated. Components were compared between the groups using t-tests. Results: A significant difference was detected in the low-frequency component between the OAP and LAI groups (P=0.046). No significant difference was found in total power or the high-frequency component between the two groups. Conclusion: Compared with OAPs, LAIs have fewer adverse effects on ANS activity, particularly the low-frequency component, as determined using a spectral analysis of heart rate variability. Keywords: long-acting injectable antipsychotics, autonomic nervous system, heart rate variability, adverse effect

We present 2 cases of coronavirus disease 2019 (COVID-19)-associated brachial plexus neuropathy. In the setting of the COVID-19 pandemic, many explanations have been proposed for this entity such as positioning-related peripheral nerve injury, microvascularinduced ischemic plexopathy, postinfectious inflammatory neuropathy, or systemic neuropathy. It is often challenging to establish a diagnosis because the potential diagnoses overlap. However, it is important for clinicians to be aware of the potential etiologies of brachial plexus neuropathy in patients with COVID-19. [ABSTRACT FROM AUTHOR]

Noriyuki Kanzaki,1 Yoshiko Ono,1 Hiroshi Shibata,1 Toshio Moritani2 1Institute for Health Care Science, Suntory Wellness Ltd, Seika-cho, Soraku-gun, 2Graduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, Kyoto, Japan Background: The aim of this study was to investigate the ability of a glucosamine-containing supplement to improve locomotor functions in subjects with knee pain.Methods: A randomized, double-blind, placebo-controlled, parallel-group comparative study was conducted for 16 weeks in 100 Japanese subjects (age, 51.8±0.8 years) with knee pain. Subjects were randomly assigned to one of the two supplements containing 1) 1,200 mg of glucosamine hydrochloride, 60 mg of chondroitin sulfate, 45 mg of type II collagen peptides, 90 mg of quercetin glycosides, 10 mg of imidazole peptides, and 5 µg of vitamin D per day (GCQID group, n=50) or 2) a placebo (placebo group, n=50). Japanese Knee Osteoarthritis Measure, visual analog scale score, normal walking speed, and knee-extensor strength were measured to evaluate the effects of the supplement on knee-joint functions and locomotor functions.Results: In subjects eligible for efficacy assessment, there was no significant group × time interaction, and there were improvements in knee-joint functions and locomotor functions in both groups, but there was no significant difference between the groups. In subjects with mild-to-severe knee pain at baseline, knee-extensor strength at week 8 (104.6±5.0% body weight vs 92.3±5.5% body weight, P=0.030) and the change in normal walking speed at week 16 (0.11±0.03 m/s vs 0.05±0.02 m/s, P=0.038) were significantly greater in the GCQID group than in the placebo group. Further subgroup analysis based on Kellgren–Lawrence (K–L) grade showed that normal walking speed at week 16 (1.36±0.05 m/s vs 1.21±0.02 m/s, P

To examine the possible age-related blood pressure (BP) deregulation in response to central hypervolemia, we measured spontaneous baroreflex sensitivity (SBRS), carotid arterial compliance (CC), and R-R interval coefficient of variation (RRICV) during basal and thermoneutral resting head-out-of-water immersion (HOWI) in 7 young (YG = 24.0 ± 0.8 years) and 6 middle-aged/older (OL = 59.3 ± 1.3 years) healthy men. Compared with basal conditions (YG = 19.6 ± 4.0 vs OL = 6.1 ± 1.5 ms/mmHg, P < 0.05), SBRS remained higher in YG than OL during rest HOWI (YG = 23.6 ± 6.6 vs OL = 9.3 ± 2.1 ms/mmHg, P < 0.05). The RRICV was significantly different between groups (YG = 6.5 ± 1.4 vs OL = 2.8 ± 0.4%, P < 0.05) under HOWI. The OL group had no increase in CC, but a significant increase in systolic BP (basal = 115.3 ± 4.4 vs water = 129.3 ± 5.3 mmHg, P < 0.05) under HOWI. In contrast, the YG group had a significant increase in CC (basal = 0.16 ± 0.01 vs water = 0.17 ± 0.02 mm²/mmHg, P < 0.05) with no changes in systolic BP. SBRS was positively related to CC (r = 0.58, P < 0.05 for basal vs r = 0.62, P < 0.05 for water). Our data suggest that age-related vagal dysfunction and reduced CC may be associated with SBRS differences between YG and OL groups, and with BP elevation during HOWI in healthy older men.